Federated Hermes Inc. Sells 5,292 Shares of LivaNova PLC (NASDAQ:LIVN)

Federated Hermes Inc. lessened its holdings in shares of LivaNova PLC (NASDAQ:LIVN) by 3.5% during the 4th quarter, Holdings Channel.com reports. The firm owned 146,579 shares of the company’s stock after selling 5,292 shares during the period. Federated Hermes Inc.’s holdings in LivaNova were worth $7,584,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of LivaNova by 10.8% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,384 shares of the company’s stock worth $641,000 after purchasing an additional 1,208 shares during the last quarter. Louisiana State Employees Retirement System bought a new position in LivaNova in the fourth quarter valued at about $781,000. Allspring Global Investments Holdings LLC boosted its holdings in LivaNova by 1.8% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 829,576 shares of the company’s stock valued at $42,922,000 after acquiring an additional 14,675 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in LivaNova by 6.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,981 shares of the company’s stock valued at $1,499,000 after acquiring an additional 1,779 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in LivaNova by 80.8% in the fourth quarter. Pacer Advisors Inc. now owns 8,102 shares of the company’s stock valued at $419,000 after acquiring an additional 3,621 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on LIVN. Barclays raised their price target on LivaNova from $57.00 to $61.00 and gave the company an “equal weight” rating in a report on Monday, February 26th. Mizuho reiterated a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Wednesday, March 27th. Robert W. Baird raised their price target on LivaNova from $56.00 to $62.00 and gave the company a “neutral” rating in a report on Thursday, February 22nd. StockNews.com raised LivaNova from a “hold” rating to a “buy” rating in a research note on Thursday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $72.00 target price on shares of LivaNova in a research note on Wednesday, March 20th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $64.40.

LivaNova Trading Up 1.7 %

NASDAQ:LIVN opened at $55.94 on Thursday. LivaNova PLC has a 1-year low of $42.75 and a 1-year high of $59.86. The business’s 50-day moving average price is $53.92 and its two-hundred day moving average price is $50.59. The company has a current ratio of 2.95, a quick ratio of 2.51 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 174.81 and a beta of 0.89.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, February 21st. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.10. The firm had revenue of $310.10 million for the quarter, compared to analyst estimates of $287.65 million. LivaNova had a return on equity of 12.23% and a net margin of 1.53%. The company’s quarterly revenue was up 12.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.81 earnings per share. On average, equities analysts expect that LivaNova PLC will post 3.01 earnings per share for the current year.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.